Morningside group (www.morningside.com) is a diversified investment group founded in 1986 by the Chan family of Hong Kong. It is engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, across Asia-Pacific, and since 1992, in Mainland China. The Morningside group was one of the earliest institutional investors in China's internet industry and in recent years has been an active investor in China's emerging biotechnology sector.
Investing in emerging biotechnology companies, Astellas Venture Management LLC (AVM) is the corporate venture capital arm of Astellas Pharma Inc., a global pharmaceutical company that orginiated in Japan. AVM is currently managing four funds.
BC Advantage is a life sciences and technology fund that focuses on BC's most promising emerging tecSeptember 8, 2011 over $55M under management.
BDC Venture Capital
BDC Venture Capital is a major venture capital investor in Canada, active at every stage of the company's development cycle, from seed through expansion, with a focus on technology-based businesses that have high growth potential and that are positioned to become dominant players in their markets. BDC Venture Capital has been involved in venture capital since 1975 and has to date invested in more than 400 companies. It currently manages approximately $500 million in companies involved in the areas of Life Sciences, Telecommunications, Information Technology and Advanced Technologies.
Discovery Capital Corporation is a venture capital investor and fund manager which focuses primarily on the enhancement of BC-based technology ventures. With over $63 million raised incrementally since 1993, Discovery Capital has grown the funds' market value significantly, realizing gains through several IPOs and sales of Investee Companies.
GrowthWorks is a recognized leader in venture capital and fund management with proven expertise in the raising and managing of capital. Managing several funds with over $800 million in assets, GrowthWorks has substantial capital resources and expertise.
Roche Venture Fund
The Roche Venture Fund invests in early stage biotech and diagnostics companies to support innovative technologies and medicines. Based in Basel, Switzerland, the Roche Venture Fund invests globally with a portfolio of over 25 companies in 10 countries.